Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: DVA stock price vs MCK: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at MCK's multiple
Needs MCK P/E.
Implied fair value · at DVA's multiple
Needs DVA P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
DAVITA INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
McKESSON CORPORATION · implied price per share
Bear
$521.24
Base
$616.65
Bull
$740.89
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
QUEST DIAGNOSTICS INC
DVA vs DGX
WEST PHARMACEUTICAL SERVICES INC
DVA vs WST
BAXTER INTERNATIONAL INC
DVA vs BAX
Cigna Group
DVA vs CI
LABCORP HOLDINGS INC.
DVA vs LH
CARDINAL HEALTH INC
DVA vs CAH
AbbVie Inc.
DVA vs ABBV
HENRY SCHEIN INC
DVA vs HSIC
PATTERSON COMPANIES, INC.
DVA vs PDCO
Zoetis Inc.
DVA vs ZTS
CVS HEALTH Corp
DVA vs CVS
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe DVA's superior margins and high ROIC are sustainable and the market will re-rate DVA toward MCK P/E multiples, then buy because the P/E-implied price of $330.09 represents 120.9% upside from $149.45; otherwise avoid or wait for de-risking because Net Debt/EBITDA of 6.0x and an Altman Z-Score of 1.57 raise meaningful financial-risk-driven downside.
DVA's current price ($149.45) is well below the P/E-based implied price of $330.09 (120.9% upside) using MCK multiple, producing a wide valuation gap. However MCK-implied outcomes span $61.40–$330.09 and DVA sits inside its historical band ($134.50–$164.40), implying outcome uncertainty despite the large upside at the top of the range.
Supporting Metrics
